World Health Organization
Avenue Appia 20
1211
Geneva 27
Tel: 00-41-22-791-21-11
Fax: +00-41-22-791-3111
Website: http://www.who.int/
Email: info@who.int
502 articles with World Health Organization
-
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
11/29/2022
Novavax, Inc. announced that the World Health Organization has issued an updated Emergency Use Listing for Nuvaxovid™ COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.
-
The Lancet Commission published a lengthy criticism of the WHO’s COVID-19 pandemic response. In turn, the WHO offered a reply to a number of the complaints.
-
German Chancellor Scholz, WHO Director-General Tedros, international ministers at World Health Summit 2022
9/13/2022
The World Health Summit and the World Health Organization as co-organizer jointly invite to the world's leading global health conference.
-
With more than 6,600 cases of monkeypox in the United States, the Biden administration declared the viral outbreak a public health emergency as cases continue to rise across the nation.
-
The announcement signals that the WHO now views the outbreak as significant enough that a coordinated global response is necessary to control it.
-
STATEMENT - Update on monkeypox in Canada - July 23, 2022
7/24/2022
On July 21, 2022, the World Health Organization convened a second meeting of its International Health Regulations Emergency Committee to assess the ongoing international monkeypox outbreak.
-
Ascletis has commenced its Phase II trial in China for its candidate drug ASC22 alongside anti-retroviral therapy for the functional cure and immune restoration of HIV-1 infection.
-
STATEMENT - Update on monkeypox in Canada - June 27, 2022
6/27/2022
On June 23, 2022, the World Health Organization Director General convened its International Health Regulations Emergency Committee to discuss the multi-country outbreak of monkeypox.
-
The WHO will decide whether to declare a public health emergency following the recent outbreaks of monkeypox, and poliovirus has been detected in London water samples.
-
Three physicians filed a lawsuit against the FDA alleging the organization acted outside its authority and with their ability to practice medicine by discouraging the use of ivermectin to treat COVID-19.
-
Monkeypox Alert: AHF Press Telcon. TODAY (6/20) at 11:00 AM PT
6/20/2022
AHF, the largest global AIDS organization with treatment clinics or operations in 45 countries, will host a Zoom Press Teleconference MONDAY, June 20, at 11:00 am PT to discuss the recent global outbreak of monkeypox, which has disproportionately affected gay men or men who have sex with men.
-
The World Trade Organization approved vaccine patent waivers to increase the availability of COVID-19 vaccines to lower-income countries.
-
The World Health Organization is giving the monkeypox virus a new name soon in an attempt to quell the stigma and discrimination that might go with it.
-
GSK reported positive headline data from a pre-specified efficacy interim analysis of the Phase III trial of its RSV vaccine.
-
Monkeypox is not COVID-19, but both are viral diseases that are front-and-center in the world of public health and epidemiology. Here's a look at the latest news on both outbreaks.
-
The WHO reports it’s too early to tell if the monkeypox outbreak could become a pandemic, but believe there is a window of opportunity to control the cases.
-
Warnings of Monkeypox went unheeded as scientists around the world began to uncover clues about the disease's origin. Here are the latest updates on the monkeypox virus.
-
Sunday night, U.S. health authorities announced that they may have found the third documented case of monkeypox in a patient in South Florida.
-
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
5/20/2022
LumiraDx Limited, a next-generation point of care diagnostics company, announced that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing by the World Health Organization in their latest response effort to combat COVID-19.
-
The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.